Recurrent acute bilateral cicatricial conjunctivitis as an adverse event of systemic adalimumab for rheumatoid arthritis
Article Sidebar
Main Article Content
Abstract
Anti-TNF-α therapies, though known for their anti-inflammatory effects, have been associated with paradoxical inflammatory reactions, of which anterior uveitis is the most common. We report a case of recurrent bilateral cicatricial conjunctivitis linked to systemic adalimumab (ADA) treatment in a 66-year-old man with rheumatoid arthritis (RA). The patient experienced worsening bilateral red eyes, blurry vision, and discomfort following each ADA injection. Examination revealed signs of cicatricial inflammation, which responded to corticosteroids but recurred after subsequent ADA doses. Despite these ocular events, adalimumab was continued due to its effective control of systemic RA, with close ophthalmic monitoring. This case suggests a potential direct association between ADA and cicatricial conjunctivitis, a previously undescribed complication. Aggressive topical corticosteroid treatment may allow the continuation of ADA without compromising systemic disease control.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Nicolela Susanna F, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect 2020;10:11. DOI: https://doi.org/10.1186/s12348-020-00202-6
Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. DOI: https://doi.org/10.1002/art.21197
Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 2018;53:49-63. DOI: https://doi.org/10.1159/000479475
Wendling D, Paccou J, Berthelot JM, et al; CRI. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10. DOI: https://doi.org/10.1016/j.semarthrit.2011.05.005
Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35:751-6. DOI: https://doi.org/10.3109/02713683.2010.486520
Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 2012;39:233-9. DOI: https://doi.org/10.3899/jrheum.110865
Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med 2016;375:932-43. DOI: https://doi.org/10.1056/NEJMoa1509852
Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016;388:1183-92. DOI: https://doi.org/10.1016/S0140-6736(16)31339-3
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79. DOI: https://doi.org/10.1016/j.pharmthera.2007.10.001
Bhamra MS, Gondal I, Amarnani A, et al. Ocular manifestations of rheumatoid arthritis: implications of recent clinical trials. Int J Clin Res Trials 2019;4:139. DOI: https://doi.org/10.15344/2456-8007/2019/139
Zlatanović G, Veselinović D, Cekić S, Zivković M, Dorđević-Jocić J, Zlatanović M. Ocular manifestation of rheumatoid arthritis—different forms and frequency. Bosn J Basic Med Sci 2010;10:323-7. DOI: https://doi.org/10.17305/bjbms.2010.2680
Puxeddu I, Caltran E, Rocchi V, Del Corso I, Tavoni A, Migliorini P. Hypersensitivity reactions during treatment with biological agents. Clin Exp Rheumatol 2016;34:129-32.
Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52. DOI: https://doi.org/10.1002/art.22918
Seve P, Varron L, Broussolle C, Denis P, Kodjikian L. Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm 2012;20:59-60. DOI: https://doi.org/10.3109/09273948.2011.623213
Matet A, Daruich A, Beydoun T, Cosnes J, Bourges JL. Systemic adalimumab induces peripheral corneal infiltrates: a case report. BMC Ophthalmol 2015;15:57. DOI: https://doi.org/10.1186/s12886-015-0047-6
Saffra N, Astafurov K. Visual loss induced by adalimumab used for plaque psoriasis. Case Rep Dermatol 2017;9:60-4. DOI: https://doi.org/10.1159/000461572
Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 2010;18:475-81. DOI: https://doi.org/10.3109/09273948.2010.495814
Chung JH, Van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. J Neurol Sci 2006;244:133-6. DOI: https://doi.org/10.1016/j.jns.2006.01.012
von Jagow B, Kohnen T. Anterior optic neuropathy associated with adalimumab. Ophthalmologica 2008;222:292-4. DOI: https://doi.org/10.1159/000140257
Kim A, Saffra N. A case report of adalimumab-associated optic neuritis. J Ophthalmic Inflamm Infect 2012;2:145-7. DOI: https://doi.org/10.1007/s12348-011-0058-2
Schechet SA, Garff K, Klima K, Campbell W, Schocket LS. Acute retinal necrosis after administration of adalimumab, a systemic antitumor necrosis factor antibody. Retin Cases Brief Rep 2018;12:307-9. DOI: https://doi.org/10.1097/ICB.0000000000000499
Marticorena-Álvarez P, Chaparro M, Pérez-Casas A, Muriel-Herrero A, Gisbert JP. Probable diffuse retinopathy caused by adalimumab in a patient with Crohn’s disease. J Crohns Colitis 2012;6:950-3. DOI: https://doi.org/10.1016/j.crohns.2012.03.015
Montero JA, Ruiz-Moreno JM, Rodríguez AE, Ferrer C, Sanchis E, Alio JL. Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur J Ophthalmol 2006;16:343-5. DOI: https://doi.org/10.1177/112067210601600225
Drury J, Hickman SJ. Internuclear ophthalmoplegia associated with anti-TNFα medication. Strabismus 2015;23:30-2. DOI: https://doi.org/10.3109/09273972.2014.999796
Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016;2:e000239. DOI: https://doi.org/10.1136/rmdopen-2015-000239
Dart JK. The 2016 Bowman Lecture—Conjunctival curses: scarring conjunctivitis 30 years on. Eye (Lond) 2017;31:301-32. DOI: https://doi.org/10.1038/eye.2016.284
Igwe CN, Robinson F, Jones SM. A novel case of ocular cicatricial pemphigoid induced by levamisole-adulterated cocaine. Eur J Ophthalmol 2021;31(1 Suppl):11-5. DOI: https://doi.org/10.1177/1120672120964756
Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye (Lond) 2003;17:886-92. DOI: https://doi.org/10.1038/sj.eye.6700576